The differences between the regimens, anti-PD1/CTLA-4 and anti-PD1/LAG-3, can be used to optimize outcomes for patients with melanoma, particularly in those who develop drug resistance.
Clinical Trials
SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis
Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of regulatory T cells (Tregs), monocytic myeloid-derived suppressor cells (M-MDSCs), and M2 macrophages in liver metastases in patients with uveal melanoma, according to data from the phase 1 PERIO-01 trial (NCT04935229) presented at the 2023 SITC Annual Meeting.
Bemcentinib Plus SOC Is Well Tolerated, But Does Not Improve Efficacy in Metastatic Melanoma
The addition of bemcentinib (BGB324) to the standard-of-care (SOC) therapies of pembrolizumab (Keytruda) or dabrafenib (Tafinlar) plus trametinib (Mekinist) was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) vs SOC alone, according to data from the phase 1b/2 BGBIL006 trial (NCT02872259).
Immunotherapy Clinical Trial Tackles Barriers to Treating Uveal Melanoma Liver Metastasis
Uveal melanoma is a rare type of eye cancer. Less than 2,000 people are diagnosed with the disease annually in the United States. It is treatable, however, roughly half of uveal melanoma patients will develop metastatic disease, most commonly to the liver, drastically reducing their chance for survival.